First EU-regulated on-chain exchange 21X taps Chainlink for tokenized securities
Key Takeaways
- 21X, the first EU-regulated on-chain exchange for tokenized securities, has integrated Chainlink data oracles.
- This partnership provides real-time, verifiable market data for tokenized securities on the Polygon blockchain.
21X, the first blockchain-based exchange licensed under the EU’s DLT Regime, has adopted Chainlink data oracles to provide real-time, on-chain market data for its tokenized securities, the companies announced Monday.
The integration, powered by the Chainlink Runtime Environment (CRE), enables verifiable market data, including best bid and ask prices with corresponding quantities, as well as last traded prices for securities listed on the 21X platform. This data is accessible in real-time on the public Polygon blockchain.
Discussing the move, Max Heinzle, CEO of 21X, said it was a “foundational step” that connects blockchains to traditional capital markets. The integration will allow 21X to securely and reliably deliver real-time, verifiable market data for 21X’s listed securities.
“By integrating Chainlink into our regulated DLT trading venue, we’re delivering the transparency, auditability, and collateral utility that institutions require to move on-chain,” Heinzle stated.
Using Chainlink’s infrastructure, which secures the majority of DeFi transactions, 21X’s market data is automatically retrieved from on-chain contracts, aggregated, and published in a standardized, machine-readable format.
“We’re excited that 21X, the first fully regulated on-chain market for trading and settlement, has adopted the Chainlink data standard,” said Fernando Vazquez, President of Banking Capital Markets at Chainlink Labs. “With Chainlink making 21X’s EU-regulated tokenized securities more usable across the on-chain economy and helping bring institutional-grade assets to DeFi protocols across the globe, this is a pivotal moment for the blockchain economy as it opens the floodgates of institutional capital to flow on-chain.”
21X plans to expand the Chainlink integration to include pre-trade data, deeper analytics, and additional asset classes.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify
In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Crypto prices
More
